Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

At the 72nd Congress of the American Society for Reproductive Medicine (ASRM)
  • USA - English


News provided by

IGENOMIX USA, LLC

Oct 17, 2016, 12:30 ET

Share this article

Share toX

Share this article

Share toX

Professor Carlos Simon
Professor Carlos Simon

Salt Lake City (UT, USA. UU.) (PRWEB) October 17, 2016 -- The research career of Professor Carlos Simón, Scientific Director of IVI and Igenomix, has been recognized during the opening ceremony of the 72nd Annual Meeting of the American Society for Reproductive Medicine (ASRM), held in Salt Lake City (Utah, USA), where he was presented with the ASRM Distinguished Researcher Award, an honorary award which has to date only been given to 11 researchers in this field, now Professor Simon is the first European to join this select group.

Professor Simon is a renowned national and international figure, with numerous awards including the prestigious “Premio Jaime I de Investigación Clinica” (Jaime I Prize for Clinical Investigation) in 2011.

Post this

His pioneering contributions, both basic and clinical, in reproductive medicine together with his essential contributions in the field, have not only helped the development of this area of medicine but also specialists around the world to improve their results and thereby help every couple that cannot conceive and dream to have their own healthy baby. All this has been the determining factor as to why Professor Simón was proposed for this award.
Professor Simon, whose scientific career has been based on investigating clinically relevant unresolved issues and looking to new technology for solutions, is today one of the most knowledgeable experts on the human endometrium. He has more than twenty awards endorsing his scientific career and half of these have been international.

"It's a real honor for me, as a clinician and research scientist, to be recognized by ASRM, one of the most important societies in the world of reproductive medicine. I am extremely proud to be a part of that small list of pioneers, " said Professor Simon after collecting his award from the ASRM President, " this award is also for my team, who started with me in IVI and followed me to Igenomix” he added.

The ASRM Distinguished Researcher Award, recognizes the work of those members of the society who have excelled in their outstanding contributions to clinical or basic research in reproduction over the past 10 years. ASRM dedicates this award to researchers who demonstrate a continuing commitment and long-term advances in research in the field of reproductive sciences as well as in the education of future scholars in this area.

About Professor Carlos Simon

Born in Spain (Valencia, 1961) Professor Carlos Simon is a specialist and Professor of Obstetrics and Gynaecology at the University of Valencia, Scientific Director of IVI and Igenomix, a Professor at Stanford University and the Baylor College of Medicine, USA.

Since 1991 he has contributed with his pioneering work and research to providing clinical solutions to problems that cause infertility. Using microarray technology, Professor Simon found the transcriptomic signature of identified genes present in human endometrial receptivity and published his findings in 20 papers, the first of which was the most cited in the Journal of Molecular Human Reproduction.

The clinical realisation of his results led to the creation of a patent to create a customized array called Endometrial Receptivity Array (ERA) designed to ascertain the molecular diagnosis of endometrial receptivity in infertile patients (Fertil Steril. 2011) and these days ASRM recognizes its proven success, which has delivered pregnancy rates of 85%. Professor Simon also created a database on endometrial receptivity that is freely available and managed by Valencia University.

The scientific impact of his work is reflected in the production of 384 articles published in international journals that total a cumulative impact factor of 1667.545. His work has received a total of 12,754 citations with an average of 34 citations per article. He has an h index of 65 and is has published 18 books in English, Spanish and Portuguese and 20 monographic notebooks, making him one of the most prolific Spanish scientists in the world.

As an inventor, his research has resulted in 16 patents, 15 international and 1 national for biotech products that are produced and distributed by Igenomix, the Spanish biotechnology company currently headed by Professor Simon.

Professor Simon is a renowned national and international figure, with numerous awards including the prestigious “Premio Jaime I de Investigación Clinica” (Jaime I Prize for Clinical Investigation) in 2011.

About Igenomix

IGENOMIX is a biotechnology company that provides advanced services in genetic reproduction. It has a wealth of experience and advanced research capabilities that has made this company one of the world leaders in its field, enabling it to provide effective solutions tailored to different infertility problems. The company has a presence in Valencia, Miami, Los Angeles, New York, Mexico D.F, Sao Paulo, Dubai and Delhi with a team of more than 165 qualified professionals worldwide.

Further information about the company at http://www.igenomix.com

About IVI

IVI was born in 1990 as the first medical institution in Spain to specialize entirely in human reproduction. Today, it has more than 50 clinics in 11 countries and is a leader in reproductive medicine.

For further company information: http://www.ivi.es

Igenomix, IGENOMIX USA, LLC, http://www.igenomix.us, +1 (305)501-4948, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.